OncoMatch/Clinical Trials/NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Is NCT07223424 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including nivolumab and pembrolizumab for renal cell carcinoma.

Phase 2RecruitingDiwakar DavarNCT07223424Data as of May 2026

Treatment: nivolumab · pembrolizumab — The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Small Cell Lung Cancer

Melanoma

Colorectal Cancer

Hepatocellular Carcinoma

Esophageal Carcinoma

Cervical Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify